126352-69-0

Basic information

• Product Name: 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE;4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(HCl salt);5-a]pyriMidine;7-tetrahydropyrazolo[1;4,5,6,7-Tetrahydropyrazolo[1,5-a]pyriMidine 2HCl;Pyrazolo[1,5-a]pyriMidine,4,5,6,7-tetrahydro-;4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidine;4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine hydrochloride
• CAS NO: 126352-69-0
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.16
• Product Categories: CHIRAL CHEMICALS
• Mol File: 126352-69-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.33
• Vapor Pressure: 0.0021mmHg at 25°C
• Refractive Index: 1.689
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.52±0.20(Predicted)
• CAS DataBase Reference: 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE(126352-69-0)
• EPA Substance Registry System: 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE(126352-69-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• Hazardous Substances Data: 126352-69-0(Hazardous Substances Data)

Usage

Uses

4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrimidine can be used as FGFR inhibitors to treat FGFR3-associated diseases, such as, cancer.

InChI:InChI=1/C6H9N3/c1-3-7-6-2-4-8-9(6)5-1/h2,4,7H,1,3,5H2

Upstream product

• 29303-21-7 6,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-5-one 
• 123-91-1 1,4-dioxane 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 126352-82-7 4-formyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine 
• 148777-84-8 3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Cephem compounds

The invention relates to an antimicrobial compound of the formula: STR1 wherein R1 is amino or a protected amino group, R2 is lower alkyl, lower alkenyl, carboxy (lower) alkyl or protected carboxy(lower)alkyl, R3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl, protected amino(lower)alkyl or lower alkanoyl, R4 is hydrogen, lower alkyl or lower alkylthio, and Z is N or CH or a pharmaceutically acceptable salt thereof.